|
Brussels, |
|
eDossier EUMED | EU Medical Devices, IVD & Biomedical Technologies | Preview version | Updated 1 July 2026
EUMED eDossier Preview
EU Medical Devices, IVD & Biomedical Technologies
EU legislation, governance, simplification agenda, EUDAMED, biomedical innovation, AI-enabled devices, research, funding and market outlook.
Preview Summary
The EU medical technology framework is entering a new phase. After the difficult implementation of the Medical Devices Regulation and the In Vitro Diagnostic Medical Devices Regulation, the European Commission has moved from emergency transition measures to a targeted simplification and competitiveness agenda.
This preview introduces the scope of the full EUMED eDossier, which analyses MDR/IVDR implementation, the 2025 targeted revision proposal, EUDAMED, notified-body bottlenecks, biomedical technologies, AI-enabled medical devices, health data, clinical evidence, market statistics, research and EU funding.
The biomedical dimension is central: EUMED covers technologies at the intersection of medicine, biology, diagnostics, data and engineering, including devices and IVDs as well as the systems that support their development, validation, monitoring and market access.
What the full eDossier covers
MDR/IVDR framework
Legal architecture, classification, conformity assessment, clinical and performance evidence, post-market surveillance and vigilance.
Simplification agenda
Analysis of the 2025–2026 targeted revision, certificate-cycle changes, burden reduction, digitalisation and critical-device availability.
EUDAMED and traceability
Mandatory modules, UDI/device registration, actors, certificates, market surveillance and database-based compliance implications.
Biomedical technologies
Diagnostics, implants, laboratory technologies, connected devices, orphan devices, breakthrough devices and bio-digital systems.
AI and software devices
Software as medical device, AI-enabled diagnostics, cybersecurity, human oversight, data governance and MDR/IVDR-AI Act interplay.
Health data and evidence
European Health Data Space, real-world evidence, HTA, clinical evidence strategies and secondary use of health data.
Market and statistics
EU market size, SMEs, employment, product diversity, trade profile, sector trends and competitiveness implications.
Research and funding
Horizon Europe, EU4Health, IHI, Digital Europe, EIC, EIT Health, HERA, IPCEI, InvestEU and regional innovation ecosystems.
Political debate
Commission, Parliament, Member States, EESC, BioMed Alliance, industry and patient-safety positions on reform and implementation.
Preview Extract
From regulatory transition to biomedical competitiveness
The central question for EU medical devices policy is no longer only whether the MDR/IVDR system can guarantee safety, but whether it can do so without delaying access to essential, innovative and biomedical technologies. The policy file has therefore moved from transitional deadline management to a more structural discussion on simplification, proportionality, evidence, notified-body capacity and patient access.
EUMED should not be read as a narrow regulatory note on devices. It is a policy-intelligence dossier on the EU medical technology ecosystem. The core legal perimeter is MDR/IVDR, but the business and biomedical perimeter is wider: medical devices, IVDs, diagnostic platforms, medical software, AI-enabled decision-support tools, connected wearables, implantable devices, laboratory technologies, performance studies, clinical evidence, cybersecurity, health data and biomedical innovation programmes.
| EUMED perimeter | Examples | Regulatory relevance |
|---|---|---|
| Medical devices | Implants, surgical instruments, imaging equipment, monitoring devices and hospital equipment. | MDR classification, clinical evaluation, notified-body certification and post-market surveillance. |
| In vitro diagnostics | Laboratory tests, companion diagnostics, genetic tests and point-of-care diagnostics. | IVDR classification, performance evaluation, reference laboratories, Class D devices and performance studies. |
| Biomedical technologies | Tissue-interfacing devices, advanced diagnostics, sensors, lab platforms and bio-digital systems. | Clinical evidence, risk management, conformity assessment and breakthrough/orphan-device debates. |
| Software and AI devices | Software as medical device, AI diagnostic systems, triage and decision-support tools. | MDR/IVDR plus AI Act, data governance, cybersecurity, transparency and human oversight. |
Available in the full Premium version: detailed legal framework, EUDAMED module-by-module analysis, simplification proposal, governance map, market data, research and funding chapter, political debate, practical checklist, 2026–2028 watchlist and reference map.
